1. Home
  2. DBVT vs WEYS Comparison

DBVT vs WEYS Comparison

Compare DBVT & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • WEYS
  • Stock Information
  • Founded
  • DBVT 2002
  • WEYS 1906
  • Country
  • DBVT France
  • WEYS United States
  • Employees
  • DBVT N/A
  • WEYS N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • WEYS Apparel
  • Sector
  • DBVT Health Care
  • WEYS Consumer Staples
  • Exchange
  • DBVT Nasdaq
  • WEYS Nasdaq
  • Market Cap
  • DBVT 250.5M
  • WEYS 299.8M
  • IPO Year
  • DBVT N/A
  • WEYS N/A
  • Fundamental
  • Price
  • DBVT $10.80
  • WEYS $33.31
  • Analyst Decision
  • DBVT Buy
  • WEYS
  • Analyst Count
  • DBVT 4
  • WEYS 0
  • Target Price
  • DBVT $14.81
  • WEYS N/A
  • AVG Volume (30 Days)
  • DBVT 26.3K
  • WEYS 14.6K
  • Earning Date
  • DBVT 07-29-2025
  • WEYS 08-05-2025
  • Dividend Yield
  • DBVT N/A
  • WEYS 3.29%
  • EPS Growth
  • DBVT N/A
  • WEYS N/A
  • EPS
  • DBVT N/A
  • WEYS 3.04
  • Revenue
  • DBVT $3,497,000.00
  • WEYS $286,762,000.00
  • Revenue This Year
  • DBVT $1,700.53
  • WEYS N/A
  • Revenue Next Year
  • DBVT $535.67
  • WEYS N/A
  • P/E Ratio
  • DBVT N/A
  • WEYS $11.10
  • Revenue Growth
  • DBVT N/A
  • WEYS N/A
  • 52 Week Low
  • DBVT $2.21
  • WEYS $25.51
  • 52 Week High
  • DBVT $12.78
  • WEYS $41.05
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 58.42
  • WEYS 52.70
  • Support Level
  • DBVT $10.53
  • WEYS $32.65
  • Resistance Level
  • DBVT $11.33
  • WEYS $34.16
  • Average True Range (ATR)
  • DBVT 0.76
  • WEYS 1.01
  • MACD
  • DBVT 0.14
  • WEYS 0.03
  • Stochastic Oscillator
  • DBVT 65.90
  • WEYS 62.73

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

Share on Social Networks: